Health Trials

Advanced Solid Tumors Harboring RAS Mutations or Amplifications

2

Review clinical trials related to Advanced Solid Tumors Harboring RAS Mutations or Amplifications. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

This is an open-label, multi-center phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of HRS-2329 in participants with advanced solid tumors harboring RAS mutations or amplifications.

Participants needed: 120
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Jiangsu HengRui Medicine Co., Ltd.Updated: Mar 6, 2026Locations: 1
Eligibility criteria

Have fully understood this study and are willing to sign the ICF, with good comp... [+6]

Toxicity (e.g., gastrointestinal reaction and skin toxicity) from prior anti-tum... [+11]

Read more
Status: Recruiting

A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.

Participants needed: 120
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Jiangsu HengRui Medicine Co., Ltd.Updated: Nov 17, 2025Locations: 1
Eligibility criteria

Have fully understood this study and are willing to sign the ICF, with good comp... [+5]

Toxicity from prior anti-tumor treatment has not recovered to Grade ≤ 1 or a lev... [+11]

Read more